NewsEvents

Your Yourlocation: Home > To explore the potential long-term effect of tiotropium bromide(136310-93-5) on lung function

"Exploring the potential long-term efficacy of tiotropium bromide(136310-93-5) on lung function (UPLIFT)" is one of the largest clinical studies of COPD to date. At 4 years, tiotropium 1-second forced expiratory (FEV1) were superior to the control group, and the control group and the treatment group were allowed to use other COPD drugs (such as ICS / LABA combination therapy).

In the UPLIFT study, analysis of all-cause mortality at the secondary end point showed a 13% reduction in all-cause mortality (p = 0.034) in the tiotropium bromide(136310-93-5) group at 4 years of treatment compared with the control group.

COPD acute exacerbation and progression of disease and decreased pulmonary function is closely related to frequent exacerbations of COPD patients with rapid decline in lung function. Cote et al. Also demonstrated a significant association between frequent exacerbations and predicted FEV1 (r = 0.22, P <0.001). Therefore, the effective reduction of acute exacerbations in patients with early COPD to delay the progress of disease is of great significance. A subgroup analysis of the UPLIFT study showed that the annual incidence of acute exacerbation in the tiotropium bromide(136310-93-5) group was 20% lower (0.56% vs 0.70%, p <0.0001) in GOLD grade II (moderate) COPD patients than in the control group.

Address:211#Zhengfeng Building,Huanbaokejiyuan, Gaoxinkaifaqu, Jinan,250100,China TEL:086-531-82375818 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved